Dirk Thye

Dirk Thye, M.D., brings approximately 20 years of drug development executive experience to Agenovir. Most recently, he served as Chief Executive Officer of Agenovir, Inc., a company developing CRISPR products targeting persistent viral infections. Agenovir was sold to Vir, Inc. in January, 2018. Prior to Agenovir Dr. Thye was Chief Medical Officer of Cidara, Inc., building and managing all aspects of drug development including the filing of several Investigational New Drug (“IND”) applications and advancement of two programs into Phase 2 clinical trials. In addition, he was instrumental in helping the company raise approximately $150 million over a one year period through multiple private financings and an initial public offering. Previously, he co-founded Cerexa and served as President for the last several years of his tenure, following the acquisition by Forest Laboratories. While at Cerexa, he led the development of ceftaroline (Teflaro®) from pre-IND to New Drug Application filing, FDA Advisory Committee and approval, and played a key role in the evaluation and acquisition of avibactam, a beta-lactamase inhibitor from Novexel, leading the joint development committee on behalf of Forest Laboratories in partnership with AstraZeneca. Avibactam in combination with ceftazidime (Avycaz®) was approved by the FDA in February 2015. Prior to Cerexa, Dr. Thye was a Founder and Senior Vice President of Clinical Development for Peninsula Pharmaceuticals (acquired by Johnson & Johnson in 2005), a company that developed doripenem (Doribax®) for severe bacterial infections in hospitalized patients. Dr. Thye has participated as a member of the board of directors or scientific advisory board member for several companies in the anti-infective area. He received his B.A. in Molecular Biology from UC Berkeley, his M.D. from UCLA, and completed his residency in Internal Medicine at Stanford University.